期刊
INFECTIOUS DISEASE REPORTS
卷 14, 期 4, 页码 537-546出版社
MDPI
DOI: 10.3390/idr14040057
关键词
COVID-19; COVID-19 vaccine; booster; heterologous prime-boost; mix-and-match
Various safe and effective COVID-19 vaccines are available, and a prime-boost vaccination regimen is recommended. Heterologous prime-boost vaccination may provide comparable immune response and address concerns such as vaccine supply, adverse effects, emerging strains, inadequate response in immunocompromised individuals, and waning immunity.
Various safe and effective COVID-19 vaccines utilizing different platforms (mRNA, adenovirus vector, inactivated virus-based) are available against SARS-CoV-2 infection. A prime-boost regimen (administration of two doses) is recommended to induce an adequate and sustained immune response. Most of these vaccines follow a homologous regimen (the same type of vaccine as priming and booster doses). However, there is a growing interest in a heterologous prime-boost vaccination regimen to potentially help address concerns posed by fluctuating vaccine supplies, serious adverse effects (anaphylaxis and thromboembolic episodes following adenovirus-based vaccines), new emerging virulent strains, inadequate immune response in immunocompromised individuals, and waning immunity. Various studies have demonstrated that heterologous prime-boost vaccination may induce comparable or higher antibody (spike protein) titers and a similar reactogenicity profile to the homologous prime-boost regimen. Based on these considerations, the Center for Disease Control and Prevention has issued guidance supporting the mix-and-match heterologous boost COVID-19 vaccine strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据